Transition Bio, Inc.
Transition Bio, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Transition Bio, Inc..
Transition Bio, Inc. is a company.
Key people at Transition Bio, Inc..
Transition Bio, Inc. is a biotechnology company developing an end-to-end drug discovery platform focused on biomolecular condensates—membrane-less organelles that drive cellular processes and disease. It analyzes these condensates using droplet microfluidics, cellular imaging, and machine learning to map, modulate, and target them for therapeutics, primarily serving pharmaceutical companies and addressing unmet needs in oncology, neurodegeneration, and neuromuscular disorders.[1][3][5] The platform solves challenges in traditional drug discovery by revealing molecular-level impacts of compounds on condensates, enabling optimization via AI; the company raised $50M in Series A funding in 2022 and has shown growth through partnerships like Voyager Therapeutics for ALS/FTD and preclinical data presentations on YTHDC1 inhibitors for MYC-driven cancers.[3][5][6]
Founded in 2020, Transition Bio emerged from a collaboration between Harvard’s Weitz Lab (physics-led droplet microfluidics) and the University of Cambridge’s Knowles Lab (biophysical chemistry), integrating expertise in physics, chemistry, biology, and machine learning to tackle biomolecular condensates.[1][3][4] Key scientific co-founders include David Weitz (Harvard physics professor), Peter St George-Hyslop (neurodegeneration expert), Sarah Teichmann (computational biology leader), and Tuomas Knowles (CEO, biophysical chemist); executive leaders like G. Kelly Martin (Executive Chairman, ex-CEO of Radius Health and Elan) and Samuel Cohen (co-founder, ex-CEO of Wren Therapeutics) bring biotech and finance experience.[1][4] Early traction came via seed funding from Lifeforce Capital, followed by the $50M Series A led by Northpond Ventures with Taiho Ventures, Bristol Myers Squibb, and others, fueling platform buildout in Cambridge, MA (with Watertown roots).[3][5]
Transition Bio rides the biomolecular condensate wave, a paradigm shift recognizing these dynamic structures' roles in phase-separated biology, gene regulation, and diseases like cancer and neurodegeneration—previously undruggable due to lack of tools.[1][3] Timing aligns with AI-biophysics convergence in drug discovery, amid booming precision medicine demand; market forces include pharma's push for novel targets post-genomics limits, with condensates implicated in >70% of proteins and rising ALS/oncology needs.[1][6] It influences the ecosystem by enabling partners like Voyager/BMS to prioritize condensate-modulating drugs, accelerating "precision medicine approaches" in AI target ID platforms, and fostering Cambridge's biotech hub alongside peers like Catamaran Bio.[1][5]
Transition Bio is poised to disrupt condensate-centric drug discovery, with near-term milestones like advancing YTHDC1 inhibitors toward IND and expanding Voyager ALS/FTD collaboration into clinical proof-of-concept.[3][6] Trends like AI-biophysics integration, multi-modal data (proteomics/imaging), and neurodegeneration focus will propel growth, potentially yielding first condensate modulators by 2027-2028 amid $100B+ biopharma R&D shift. Its influence may evolve from platform enabler to lead developer, redefining "unsolvable" targets and cementing its highflier status in biotech's molecular frontier—bridging physics and medicine for transformative therapies.[1][3]
Key people at Transition Bio, Inc..
